National Coagulation Centre, St. James's Hospital, Dublin, Ireland.
Irish Centre for Vascular Biology, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland.
Blood Adv. 2018 Jul 24;2(14):1784-1791. doi: 10.1182/bloodadvances.2018017418.
Gynecological bleeding is frequently reported in women with von Willebrand disease (VWD). Low von Willebrand factor (VWF) may be associated with significant bleeding phenotype despite only mild plasma VWF reductions. The contribution of gynecological bleeding to this phenotype has yet to be described. The optimal clinical bleeding assessment tool (BAT) to evaluate bleeding remains unclear. Using a standardized approach to phenotypic assessment, we evaluated gynecological bleeding and directly compared the Condensed Molecular and Clinical Markers for the Diagnosis and Management of type 1 VWD (Condensed MCMDM-1 VWD) and International Society on Thrombosis and Haemostasis (ISTH) BAT scores in 120 women enrolled in the Low von Willebrand in Ireland Cohort study. Heavy menstrual bleeding (HMB) was reported in 89% of female participants; 45.8% developed iron deficiency. Using identical data, Condensed MCMDM-1 VWD menorrhagia domain scores were significantly lower than ISTH BAT scores (2 vs 3; < .0001), the discrepant results related to 40% of women not seeking medical consultation for HMB, reducing the sensitivity of the Condensed score. For those who reported HMB to physicians, the low VWF diagnosis was not expedited (age at diagnosis 34.2 vs 33.4 years in women failing to present; = .7). Postpartum hemorrhage (PPH) was self-reported in 63.5% of parous women (n = 74); 21.6% required transfusion, critical care, radiological, or surgical intervention. Our data demonstrate that gynecological bleeding is frequently reported in women with low VWF; despite pregnancy-related increases in plasma VWF levels, these women may experience PPH. Defining the optimal management approach for these patients requires further research. This trial was registered at www.clinicaltrials.gov as #NCT03167320.
妇科出血在血管性血友病(VWD)女性中经常发生。尽管血浆 VWF 水平仅有轻度降低,但低 VWF 可能与明显的出血表型相关。妇科出血对这种表型的贡献尚未被描述。评估出血的最佳临床出血评估工具(BAT)仍不清楚。我们使用标准化的表型评估方法,评估了 120 名参加爱尔兰低 VWF 队列研究的女性的妇科出血,并直接比较了简化的分子和临床标志物在 1 型 VWD 诊断和管理中的应用(简化的 MCMDM-1 VWD)和国际血栓与止血学会(ISTH)BAT 评分。89%的女性参与者报告有月经过多;45.8%出现缺铁。使用相同的数据,简化的 MCMDM-1 VWD 月经过多域评分明显低于 ISTH BAT 评分(2 对 3;<.0001),结果不一致的原因是 40%的女性因月经过多未寻求医疗咨询,降低了简化评分的敏感性。对于那些向医生报告月经过多的女性,低 VWF 的诊断并没有加快(诊断时年龄为 34.2 岁,未就诊女性为 33.4 岁;=.7)。74 名经产妇中,63.5%(n = 74)自述有产后出血(PPH);21.6%需要输血、重症监护、放射或手术干预。我们的数据表明,低 VWF 女性经常出现妇科出血;尽管血浆 VWF 水平在妊娠期间增加,但这些女性可能会发生 PPH。进一步研究需要确定这些患者的最佳管理方法。该试验在 www.clinicaltrials.gov 上注册,编号为 #NCT03167320。